Author:
Xu Xuegu,Chen Chaojie,Liu Ya-nan,Meng Xiaolei,Cai Jian-ping,Xu Ren-ai
Funder
National Key Research and Development Program of China
Subject
General Chemical Engineering,General Chemistry
Reference19 articles.
1. U.S. Department of Health and Human Services, Food and Drug Administration, Bioanalytical Method Validation Guidance for Industry, 2018 (accessed 19 June 2020) https://www.fda.gov/media/70858/download.).
2. Identification and characterization ofin silico, in vivo, in vitro, and reactive metabolites of infigratinib using LC-ITMS: bioactivation pathway elucidation andin silicotoxicity studies of its metabolites;Al-Shakliah;RSC Adv.,2020
3. Investigation of metabolic degradation of new ALK inhibitor: Entrectinib by LC-MS/MS;Attwa;Clin. Chim. Acta,2018
4. Detection and characterization of olmutinib reactive metabolites by LC-MS/MS: Elucidation of bioactivation pathways;Attwa;J. Sep. Sci.,2020
5. Metabolic stability assessment of new PARP inhibitor talazoparib using validated LC-MS/MS methodology: in silico metabolic vulnerability and toxicity studies;Attwa;Drug. Des. Devel. Ther.,2020
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献